Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1993-09-30
1995-07-04
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
A61K 31255
Patent
active
054300576
ABSTRACT:
Stable parenteral formulations of busulfan safe for parenteral administration are disclosed that exhibit improved bioavailability and optimize high dose busulfan therapy against malignant disease.
REFERENCES:
Medication Package Insert for Methotrexate, Lederle. 1992.
Giles et al., "A Platelet Release Defect Induced by Aspirin or Penicillin G Does Not Increase Gastrointestinal Blood Loss in Thrombocytopenic Rabbits," Haematology, vol. 57, No. 1, 1984, pp. 17-23.
Bhagwatwar et al., "In Vitro and In Vivo Evaluations of Intravenous Busulfan Formulation," Pharmaceutical Research, vol. 10, No. 10, Oct. 1993, p. S190.
Harshal et al., "Development of Intravenous Formulation of Busulfan," Pharmaceutical Research, vol. 9, No. 10, 1992, p. S200.
J. E. F. Reynolds, "Busulfan," Martindale, The Extra Pharmacopoeia, 1989, The Pharmaceutical Press, London, pp. 603-604.
Bhagwatwar, et al., "Formulation and Pharmacokinetics of Intravenous (I.V.) Busulphan," Proceedings of the American Association for Cancer Research, vol. 34, Mar. 1993, p. 269.
Hagihara, Database WPI, Week 8916, Derwent Publications Ltd., London, GB; AN 89-117247 * JP, A, 1 061 429 8 Mar. 1989 see abstract.
Andersson et al., "In Vitro and In Vivo Evaluations of Intravenous Busulfan Formulation," American Assoc. of Clinical Pharmacists, Annual Meeting, Nov. 1993. Abstract only.
Bhagwatwar et al., "Formulation and Pharmacokinetics of Intravenous (I.V.) Busulphan (BU) in the Rat," American Association for Cancer Research, Orlando, Florida meeting, May 19-23, 1993. Abstract only.
Blaise et al., "A Randomized Study OD CY-TBI vs BUS-CY+ALLO BMT for ANL in First CR: A Gegmo Study," BMT Suppl., 26, 1990, Abstract only.
Buckner et al., "A Randomized Study Comparing Two Transplant Regimens for CML in Chronic Phase (CP)," Blood, 80(10) (Suppl. 1):277, 1992. Abstract only.
Copelan et al., "Marrow Transplantation Following Busulfan and Cyclophosphamide for Chronic Myelogenous Leukaemia in Accelerated or Blastic Phase," British Journal of Haematology, 71:487-491, 1989.
Giles et al., "A Platelet Release Defect Induced by Aspirin or Penicillin G Does Not Increase Gastrointestinal Blood Loss in Thrombocytopenic Rabbits," British Journal of Haematology, 57(1):17-23, 1984. Abstract only.
Grochow et al., "Busulfan Disposition in Children," Blood, 75(8):1723-1727, 1990.
Grochow et al., "Pharmacokinetics of Busulfan: Correlation with Veno-Occlusive Disease in Patients Undergoing Bone Marrow Transplantation," Cancer Chemotherapy and Pharmacology, 25:55-61, 1989.
Hagenbeek, A., "Introduction of the BN Myelocytic Leukaemia," Leukemia Research, 1:85-90, 1977.
Hagenbeek et al., "Proliferation Kinetics of the BNML Leukaemia In Vivo, " Leukemia Research, 1(2/3):99-101, 1977.
Hassan et al., "Cerebrospinal Fluid and Plasma Concentrations of Busulfan During High-Dose Therapy," Bone Marrow Transplantation, 4:113-114, 1989.
Hassan et al., "Pharmacokinetics of High-Dose Busulphan in Relation to Age and Chronopharmacology," Cancer Chemotherapy and Pharmacology, 28:130-134, 1991.
Hassan et al., "In Vivo Distribution of [.sup.11 C]-Busulfan in Cynomolgus Monkey and in the Brain of a Human Patient," Cancer Chemotherapy and Pharmacology, 30:81-85, 1992.
Hassan et al., "Pharmacokinetic and Metabolic Studies of High-Dose Busulphan in Adults," Eur. J. Clin. Pharmacol., 36:525-530, 1989.
Lu et al., "Preliminary Results of High-Dose Busulfan and Cyclophosphamide with Syngeneic or Autologous Bone Marrow Rescue," Cancer Treatment Reports, 68 (5):711-717, 1984.
Kitamura et al., "Anesthetic Management of Five Patients with Polycythemia Rubra Vera. Importance of Preoperative Managements," Jpn. J. Anesthesiol., 28(5):512-517, 1979. Abstract only.
Miller et al., "A Randomized Trial of Busulfan-Cyclophosphamide (BU-CY) versus Cyclophamide-Total Body Irradiation (CY-TBI) as Preparative Regimen for Patients with Chronic Myelogenous Leukemia (CML)," Blood, 78:1155, 1991. Abstract only.
"Methods of Development of New Anticancer Drugs," National Cancer Institute Monograph 45, pp. 147-153, Mar., 1977.
Peters et al., "Clinical and Pharmacologic Effects of High Dose Single Agent Busulfan With Autologous Bone Marrow Support in the Treatment of Solid Tumors," Cancer Research, 47:6402-6406, 1987.
Schwertfeger et al., "Early Toxicity of Busulfan/Cyclophosphamide versus TBI/Cyclophosphamide Conditioning for Allogeneic Bone Marrow Transplantation in Patients with Chronic Myelogenous Leukemia," Blood, 80(10) (Suppl. 1):2125, 1992. Abstract only.
Sharkis and Santos, "Bone Marrow Transplantation in a BN Rat Model of Acute Myelogenous Leukemia (AML)," Leukemia Research, :251-252, 1977.
Sheridan et al., "High-Dose Chemotherapy with Busulphan and Cyclophosphamide and Bone-Marrow Transplantation for Drug-Sensitive Malignancies in Adults: A Preliminary Report," The Medical Journal of Australia, 151:379-385, 1989.
Tutschka and Santos, "Bone Marrow Transplantation in the Busulfan-Treated Rat," Transplantation, 20(2):101-106, 1975.
Vassal et al., "Dose-Dependent Neurotoxicity of High-Dose Busulfan in Children: A Clinical and Pharmacological Study," Cancer Research, 50:6203-6207, 1990.
Vassal et al., "Pharmacokinetics of High-Dose Busulfan in Children," Cancer Chemotherapy and Pharmacology, 24:386-390, 1989.
Vaughan et al., "Improved Results of Allogeneic Bone Marrow Transplantation for Advanced Hematologic Malignancy Using Busulfan, Cyclophosphamide and Etoposide as Cytoreductive and Immunosuppressive Therapy," Bone Marrow Transplantation, 8:489-495, 1991.
Dialog Search Report printed Mar. 31, 1993.
Andersson Borje S.
Bhagwatwar Harshal P.
Chow Diana S. L.
Board of Regents , The University of Texas System
Henley III Raymond
Spivack Phyllis G.
University of Houston-University Park
LandOfFree
Parenteral busulfan for treatment of malignant disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parenteral busulfan for treatment of malignant disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral busulfan for treatment of malignant disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-760443